Can PharmAla’s three year stability program de risk MDMA distribution challenges?
PharmAla will generate three year stability data for LaNeo MDMA. Discover how this could shape packaging, regulation, and commercialization.
Pharma & Biotech
Features & Analysis
Recursion Pharmaceuticals to spotlight self-driving lab model at NVIDIA GTC 2026
Recursion Pharmaceuticals spotlights its self-driving lab model at NVIDIA GTC 2026. Explore what this means for AI drug discovery and regulation.
Pharma & Biotech
Novo Nordisk’s CagriSema misses non-inferiority against tirzepatide: Why a 23% weight loss still reshapes the obesity pipeline
Novo Nordisk A/S disclosed headline Phase 3 data from the REDEFINE 4 trial showing that CagriSema, its fixed-dose combination of cagrilintide and semaglutide, achieved 23 percent weight loss over 84 weeks in people with obesity but failed to meet the primary endpoint of non-inferiority versus tirzepatide. The open-label head-to-head study compared once-weekly CagriSema 2.4 mg/2.4
Medical Devices & Diagnostics
What InventHelp’s heat therapy mitten reveals about the limits of consumer pain devices
InventHelp’s heat therapy mitten targets hand pain, but what does it really change? Explore the evidence, regulatory gaps, and limits of consumer pain devices.
Pharma & Biotech
How Sōlaria Biō is positioning Bōndia for credibility in a crowded bone health market
Sōlaria Biō validates gut delivery and control of Bōndia microbes. Read what the study really means for bone health and medical foods.
Medical Devices & Diagnostics
What Guerbet’s pediatric gadopiclenol label expansion reveals about the future of MRI contrast agents
FDA approval expands Guerbet’s gadopiclenol into neonates, reinforcing half-dose MRI contrast strategies. Find out what this changes for pediatric imaging.
Pharma & Biotech
Partner Therapeutics’ zenocutuzumab data adds nuance to progression-driven treatment decisions in NRG1-positive lung cancer
Find out how zenocutuzumab treatment beyond progression could change care for NRG1 fusion-positive lung cancer and what clinicians should watch next.
Medical Devices & Diagnostics
Why Edwards Lifesciences is betting on transcatheter replacement to solve tricuspid regurgitation
Find out how transcatheter tricuspid valve replacement is reshaping treatment options for severe regurgitation and what clinicians are watching next.
Pharma & Biotech
Are lymphatic system supplements moving from folklore to functional claims? A look at PureHealth Research
Explore what PureHealth Research’s lymphatic supplement launch reveals about evidence gaps, regulation, and risks in botanical congestion relief.
Pharma & Biotech
Why AltaPointe’s ketamine-assisted protocol could reshape opioid withdrawal management
Find out how a low-dose ketamine protocol may help fentanyl users start buprenorphine faster and with less withdrawal discomfort.